OSI says Tarceva to be reviewed by FDA committee for use as...

Full story: M2.com

OSI says Tarceva to be reviewed by FDA committee for use as first-line maintenance therapy in advanced NSCLC Published in M2Europharma on Monday, 16 November 2009 at 21:09 GMT 16 November 2009 - US-based OSI Pharmaceuticals Inc said today that FDA's Oncologic Drugs Advisory Committee will review the use of Tarceva as a first-line maintenance ...

Leave a Comment

Comments

Type in your comments to post to the forum

Name
(appears on your post)

Comments

Type the numbers you see in the image on the right:

Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Other Recent OSI Pharmaceuticals Discussions

Topic	Updated	Last By	Comments
OSA Phara to leave LI for Westchester (Jul '09)	Jul '09	N0-Bama	90
The OSI lesson: If you can't build it, they wil... (Jul '09)	Jul '09	Walt Kowalski	45
OSI's gain is Long Island's loss	Jul '09	do it do it	8
Take if from OSI: This is no way to foster biot...	Jul '09	Mike	3
OSI Pharmaceuticals leaving LI for Westchester (Jul '09)	Jul '09	Spencer	23
OSI Pharamaceuticals to leave LI for Westchester (Jul '09)	Jul '09	Animal Testi...	11
OSI Pharmaceuticals leaving LI for Westchester	Jul '09	Word	1